153 related articles for article (PubMed ID: 37559004)
1. Impact of web application support versus standard management on adherence with adjuvant hormone therapy in patients treated for breast cancer: the WEBAPPAC study.
Gernier F; Grellard JM; Dupont C; Castel H; Fernette M; Lahaye F; Charles RM; Leroux T; Ory C; Faveyrial A; Morel A; Emile G; Levy C; Segura C; Allouache D; Johnson A; Geffrelot J; Gunzer K; Lelaidier A; Girault G; Dubot-Poitelon C; San C; Lequesne J; Clarisse B
BMC Cancer; 2023 Aug; 23(1):736. PubMed ID: 37559004
[TBL] [Abstract][Full Text] [Related]
2. THRIVE study protocol: a randomized controlled trial evaluating a web-based app and tailored messages to improve adherence to adjuvant endocrine therapy among women with breast cancer.
Paladino AJ; Anderson JN; Krukowski RA; Waters T; Kocak M; Graff C; Blue R; Jones TN; Buzaglo J; Vidal G; Schwartzberg L; Graetz I
BMC Health Serv Res; 2019 Dec; 19(1):977. PubMed ID: 31856812
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
4. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
5. A Machine Learning Model to Predict Patients' Adherence Behavior and a Decision Support System for Patients With Metastatic Breast Cancer: Protocol for a Randomized Controlled Trial.
Masiero M; Spada GE; Sanchini V; Munzone E; Pietrobon R; Teixeira L; Valencia M; Machiavelli A; Fragale E; Pezzolato M; Pravettoni G
JMIR Res Protoc; 2023 Dec; 12():e48852. PubMed ID: 38096002
[TBL] [Abstract][Full Text] [Related]
6. Telehealth system (e-CUIDATE) to improve quality of life in breast cancer survivors: rationale and study protocol for a randomized clinical trial.
Galiano-Castillo N; Ariza-García A; Cantarero-Villanueva I; Fernández-Lao C; Díaz-Rodríguez L; Legerén-Alvarez M; Sánchez-Salado C; Del-Moral-Avila R; Arroyo-Morales M
Trials; 2013 Jun; 14():187. PubMed ID: 23799886
[TBL] [Abstract][Full Text] [Related]
7. Home-based multidimensional survivorship programmes for breast cancer survivors.
Cheng KKF; Lim YTE; Koh ZM; Tam WWS
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD011152. PubMed ID: 28836379
[TBL] [Abstract][Full Text] [Related]
8. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors.
Uslu Y; Kocatepe V; Sezgin DS; Uras C
Support Care Cancer; 2023 Apr; 31(5):285. PubMed ID: 37079089
[TBL] [Abstract][Full Text] [Related]
11. A telehealth intervention for symptom management, distress, and adherence to adjuvant endocrine therapy: A randomized controlled trial.
Jacobs JM; Post K; Massad K; Horick NK; Walsh EA; Cohn J; Rapoport CS; Clara AJ; Antoni MH; Safren SA; Partridge AH; Peppercorn JM; Park ER; Temel JS; Greer JA
Cancer; 2022 Oct; 128(19):3541-3551. PubMed ID: 35924869
[TBL] [Abstract][Full Text] [Related]
12. The impact of medication side effects on adherence and persistence to hormone therapy in breast cancer survivors: A quantitative systematic review.
Fleming L; Agnew S; Peddie N; Crawford M; Dixon D; MacPherson I
Breast; 2022 Aug; 64():63-84. PubMed ID: 35609380
[TBL] [Abstract][Full Text] [Related]
13. Exercise therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE; Rickett K; Feng S; Vagenas D; Woodward NE
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012988. PubMed ID: 31994181
[TBL] [Abstract][Full Text] [Related]
14. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
15. Does a homeopathic medicine reduce hot flushes induced by adjuvant endocrine therapy in localized breast cancer patients? A multicenter randomized placebo-controlled phase III trial.
Heudel PE; Van Praagh-Doreau I; Duvert B; Cauvin I; Hardy-Bessard AC; Jacquin JP; Stefani L; Vincent L; Dramais D; Guastalla JP; Blanc E; Belleville A; Lavergne E; Pérol D
Support Care Cancer; 2019 May; 27(5):1879-1889. PubMed ID: 30194492
[TBL] [Abstract][Full Text] [Related]
16. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Goel S; Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
18. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
King MT; Link EK; Whelan TJ; Olivotto IA; Kunkler I; Westenberg AH; Gruber G; Schofield P; Chua BH;
Lancet Oncol; 2020 May; 21(5):685-698. PubMed ID: 32203696
[TBL] [Abstract][Full Text] [Related]
19. Adherence to adjuvant hormonal therapy in localised breast cancer.
Davies S; Voutsadakis IA
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13729. PubMed ID: 36207823
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
